Company: RPTX
Filing Date: 2025-11-20
Form Type: DEFA14A
Source: 0001193125-25-290058
Chunk: 1

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-20
Form: DEFA14A
Chunk 1
---
 officers of Repare, shareholders owning approximately 40% of Repare’s issued and outstanding Common Shares have now agreed to vote their Common Shares in favor
of the special resolution approving the Transaction.

About Repare Therapeutics Inc.

Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of
novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s clinical-stage pipeline includes RP-3467,
a Phase 1 Polq ATPase inhibitor; and RP-1664, a Phase 1 PLK4 inhibitor. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly
Twitter) and LinkedIn.

Additional Information and Where to Find It

The Company intends to file with the SEC and furnish to its shareholders a proxy statement on Schedule 14A, as well as other relevant documents concerning the
proposed transaction. The proxy statement will contain important information about the proposed transaction and related matters. Investors and security holders of the Company are urged to carefully read the entire proxy statement (including any amendments or supplements thereto) when it becomes available because it will contain important information about the proposed transactions.A definitive proxy statement will be sent to the shareholders of the Company seeking any required
shareholder approvals.

Investors and security holders of the Company will be able to obtain a free copy of the proxy statement, as well as other relevant
filings containing information about the Company and the proposed transaction, including materials that will be incorporated by reference into the proxy statement, without charge, at the SEC’s website () or from the
Company by contacting the Company’s Investor Relations at (857) 412-7018, by submitting a contact form on the Company’s website at https://www.reparerx.com/contact/, or by going to the
Company’s Investor Relations page on its website at https://ir.reparerx.com/investor-relations and clicking on the link titled “SEC Filings.”

Participants in the Solicitation

The Company and certain of its directors, executive officers and employees may be deemed to be participants in the solicitation of proxies in respect of the
proposed transaction. Information regarding the interests of the Company’s directors and executive officers and their ownership of the Company’s common shares is set forth in the Company’s annual report on Form 10-K filed with the SEC on March 3, 2025 and the Company’s proxy